JANX

MKT CAP:$855M

Janux Therapeutics Inc

Market Cap

$855M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.36-$0.29 (-2.12%)

Jun 5, 2026

52W High $34.7452W Low $12.18

Company Details

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platform...

CEO

—

IPO Date

Jun 11, 2021

Website

www.januxrx.com

Key Metrics TTM

Revenue

$22M

+2522.9% YoY

Net Income

-$114M

EPS (Diluted)

Free Cash Flow

-$78M

Revenue / Share

$0.34

Gross Margin

51.6%

Operating Margin

-726.3%

Net Margin

-529.7%

FCF Margin

-363.2%

P/S

39.6x

P/E

Earnings Reports

Q1 2026

May 7, 2026

$4M

FY 2025

Feb 26, 2026

$10M-5.6%

Q4 2025

Feb 26, 2026

$8M+192.6%

Q3 2025

Nov 6, 2025

$10M+2177.9%

Q2 2025

Aug 7, 2025

$0-100.0%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee